


71 patients assessed for eligibility
(Sep2019 - Jan2022)



Supplemental Fig 1: Consolidated Standards of Reporting Trials (CONSORT) flow diagram of the study.
EMR: electronic medical record; len/pem: combination lenvatinib and pembrolizumab.